Browse our materials
for additional information

The following is a searchable and filterable list of our news posts, press releases, white papers, articles, scientific posters, and much more.
If you can’t find something, please let us know and we’ll reach out to you as soon as we can.

Filter your resources:
  • Rewiring Drug Research and Development through Human Data-Driven Discovery (HD3)

    Jackson, D.B. et al. Pharmaceutics 2023, 15(6), 1673
    Open resource
  • Determination of the Cancer Genome Atlas (TCGA) Endometrial Cancer Molecular Subtypes Using the Variant Interpretation and Clinical Decision Support Software MH Guide

    Mustea, A. et al. Cancers 2023, 15(7), 2053
    Open resource
  • Application of a patient-centered reverse translational systems-based approach to understand mechanisms of an adverse drug reaction of immune checkpoint inhibitors

    Kim, S. et al. Clin Transl Sci. 2022 Jun;15(6):1430-1438. doi: 10.1111/cts.13254
    Open resource
  • Evaluation of the TruSight Tumor 170 Assay and Its Value in Clinical Diagnostics

    Heydt, C. et al. J. Mol. Pathol. 2022, 3(1), 53-67;
    Open resource
  • Whole patient knowledge modeling of COVID-19 symptomatology reveals common molecular mechanisms

    Brock, S. et al. Front. Mol. Med. 2022, 2:1035290.
    Open resource
  • The COVID-19 explorer – An integrated, whole patient knowledge model of COVID-19 disease

    Brock, S. et al. Front. Mol. Med. 2022, 2:1035215.
    Open resource
  • Target adverse event profiles for predictive safety in the postmarket setting

    Peter Schotland, Rebecca Racz, David B. Jackson, Theodoros G. Soldatos, Robert Levin, David G. Strauss and Keith Burkhart. Clinical Pharmacology & Therapeutics Volume 109, Issue 5, Pages: 1159-1362 (May 2021)
    Open resource
  • A case study of a patient-centered reverse translational systems-based approach to understand adverse event profiles in drug development

    Kim, S. et al. Clin Transl Sci . 2022 Apr;15(4):1003-1013. doi: 10.1111/cts.13219
    Open resource
  • Advancing drug safety science by integrating molecular knowledge with post‐marketing adverse event reports

    Soldatos, T. G. et al. CPT Pharmacometrics Syst Pharmacol. 2022 May;11(5):540-555. doi: 10.1002/psp4.12765
    Open resource
GDPR Cookie Consent with Real Cookie Banner